Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...

The transition to outsourced offshore upstream manufacturing is expected to deliver substantial improvements in gross margin, EBITDA and cashflow generation. The move is part of a broader strategic ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...

SAS Viya Essentials rapidly deploys select SAS Viya products using SAS Managed Cloud Services Thursday, 20 November 2025 - SAS, a global ...

This collaboration supports the advancement of the EpiCapture test, which is currently in late-stage development, to regulatory approval and commercialization. This initiative is part of Trinity ...

Feminists and conservatives are uniting in a global push to end surrogacy, sparking fierce debate over bodily autonomy and ...

The eighth edition of the initiative has unveiled the 12 projects partaking in its Impact Lab, focusing on stories that ...

ABL Diagnostics (Euronext Paris: ABLD), a French company specializing in advanced molecular diagnostics, announces the signing of an exclusive distribution agreement with Eurobio Scientific (Euronext ...

Merck & Co., Inc. acquires Cidara Therapeutics, Inc. for $9.2bn, boosting its pipeline with CD388's strong flu data. Click ...

Thousands of mailers, social media posts and television commercials are pushing the city of Arlington to restore its ...

The post Stocks Sink Again: Market Analysis for Tuesday Nov 18th, 2025 appeared first on Stock Target Advisor.

Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced that Palmetto GBA, the Medicare Administrative Contractor that administers the Molecular ...